| 13 / Čes. slov. Farm. 2026;75(1):8-13 / ČESKÁ A SLOVENSKÁ FARMACIE www.csfarmacie.cz AKTUÁLNÍ FARMAKOTERAPIE Idiopatické intersticiální plicní procesy – přehled terapie 7. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475-82. 8. Mankikian J, Caille A, Reynaud-Gaubert M, et al; EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. 9. Lee SH, Park MS, Kim SY, et al. Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study. Respir Res. 2017;18(1):204. 10. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177(12):1338-47. 11. Buschulte K, Kabitz HJ, Hagmeyer L, et al. Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry. Respir Res. 2024;25(1):113. 12. Flaherty KR, Wells AU, Cottin V, et al; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019;381(18):1718-1727. 13. Radzikowska E, Fijolek J. Update on cryptogenic organizing pneumonia. Front Med (Lausanne). 2023;10:1146782. 14. Hellemons ME, Moor CC, von der Thüsen J, et al. Desquamative interstitial pneumonia: a systematic review of its features and outcomes. Eur Respir Rev 2020;29(156):190181. 15. Valladares C, Narvel A, Koutsenko B, et al. Examining the Role of Corticosteroids in the Management of Acute Interstitial Pneumonia: A Systematic Review. J Clin Med Res. 2025;17(4):223-230. 16. Murillo AD, Castrillon AI, Serrano CD, Fernandez-Trujillo L. Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review. BMC Pulm Med 2024;24(1):74. 17. Sergew A, Fernández Pérez ER. Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome. Semin Respir Crit Care Med. 2016;37(3):441-56. 18. Lawrence A, Myall KJ, Mukherjee B, Marino P. Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease. Life (Basel). 2024;14(9):1203. 19. Ang HL, Schulte M, Chan RK, et al. Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Chest. 2024;166(4):778-792. 20. Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021;384(4):325-334. 21. Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. Eur Respir J. 2023;61(6):2202414. 22. Nathan SD, Behr J, Cottin V, et al. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2022;9(1):e001310. 23. Yogeswaran A, Hassoun PM, Saleh K, et al.; PVRI-GoDeep-Consortium. Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. Am J Respir Crit Care Med. 2025. doi: 10.1164/ rccm.202412-2371OC. 24. Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265-75. 25. Kim MJ, Yang J, Song JW. Acute exacerbation of progressive pulmonary fibrosis: incidence and outcomes. Respir Res. 2024;25(1):415. 26. Srivali N, De Giacomi F, Moua T, Ryu JH. Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review. Thorax. 2025;80(3):140-149. 27. Yamakawa H, Sato S, Ohta H, et al. Baricitinib for Acute Exacerbation in Idiopathic Interstitial Pneumonias: A Preliminary Study Using Propensity Score Matching. Respiration. 2025:1-12. 28. Creamer AW, Barratt SL. Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial. Breathe (Sheff). 2019;15(2):140-143. 29. Lin LY, Wu YC, Wu JS, et al. Oxygen therapy for exercise capacity in fibrotic interstitial lung disease: A systematic review and meta-analysis of randomised controlled trials. Respir Med. 2024;227:107657. 30. Khor YH, Palm A, Wong AW, et al. Effects of long-term oxygen therapy on acute exacerbation and hospital burden: the national DISCOVERY study. Thorax. 2025;80(6):378-384. 31. Palm A, Ekström M. Hypoxemia severity and survival in ILD and COPD on long-term oxygen therapy - The population-based DISCOVERY study. Respir Med. 2021;189:106659. 32. Özmen İ, Yıldırım E, Karakış M, et al. Are the gains from pulmonary rehabilitation the same in idiopathic pulmonary fibrosis and other interstitial lung diseases? Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(3):e2024038. 33. Zhao Q, Mo N, Li R, et al. Effects of exercise training on exercise capacity of patients with interstitial lung disease: a systematic review and meta-analysis. BMC Pulm Med. 2025;25(1):356. 34. Selman M, Buendia-Roldan I, Pardo A. Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis. Eur Respir J. 2025;65(5):2402418. 35. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(11):1349-1379. 36. Yang L, Xiang Z, Dai M, et al. Prognosis of Lung Transplantation in Patients with Acute Exacerbations of Interstitial Lung Disease: A Meta-Analysis Based on Cohort Studies. Ann Thorac Cardiovasc Surg. 2024;30(1):24-00086. 37. Warrior K, Sayad K, O'Hara CP, Dilling DF. Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplant Outcomes. Transplantation. 2024;108(6):14601465. 38. Dotan Y, Vaidy A, Shapiro WB, et al. Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest. 2018;154(4):818-826. Psychofarmaka v kazuistikách 2. aktualizované a rozšířené vydání Ivana Tašková a kol. Psychofarmaka patří k nejčastěji předepisovaným látkám, a to jak v psychiatrii, tak v interních oborech, v neurologii aj. I velmi erudovaný lékař se při preskripci psychofarmak nezřídka dostává do situace, ve které je v daném okamžiku těžké se správně rozhodnout, přičemž dohledání správného řešení by trvalo řadu hodin. Autorky této praktické monografie předkládají pečlivě vybrané reálné situace z běžné praxe, a to s modelovým řešením, které je jak vyzkoušené, tak podložené medicínou založenou na důkazech. Specifickou problematikou jsou na jedné straně polymorbidní nemocní a senioři, na druhé straně těhotné či kojící ženy. Důraz je kladen na přehlednost a farmakologické poznámky jsou graficky zpracovány do praktických tabulek a boxů tak, aby z knihy mohl těžit každý lékař či farmaceut zabývající se psychofarmaky ve své každodenní praxi. Maxdorf 2025, 436 str., barevné ilustrace, edice Jessenius ISBN: 978-80-7345-799-0 Cena: 895 Kč Formát: 154 × 230 mm, pevná KNIŽNÍ NOVINKA
RkJQdWJsaXNoZXIy NDA4Mjc=